Market News
Stay updated with the latest market trends, earnings, and economic indicators.
Biocon shares rise 1% after billionaire Kiran Mazumdar-Shaw names niece as successor
Biocon's chairperson, Kiran Mazumdar-Shaw, has named her niece, Claire Mazumdar, as her successor, sparking a more than 1% jump in the company's shares. Shaw, who founded Biocon over 40 years ago, expressed confidence in Claire's ability to lead the company's future growth, driven by advanced biotech and AI.
Kiran Mazumdar-Shaw names niece as successor, but she is ‘not hanging up boots yet’; who is Claire Mazumdar?
Kiran Mazumdar of Biocon names her niece, Claire Mazumdar, as her successor, with a gradual transition over five years. She remains focused on advancing biotechnology and AI integration within the company while preparing for growth.
Claire Mazumdar: A silent force behind a $1.6 billion firm may write Biocon's future scripts
Biocon founder Kiran Mazumdar-Shaw has named her niece, Claire Mazumdar, as her successor. Claire Mazumdar, a successful CEO of Bicara Therapeutics, brings scientific expertise and deal-making skills. She is poised to lead Biocon into its next growth phase. The company is focusing on biosimilars and advanced biologics.
Biocon’s Kiran Mazumdar-Shaw chooses niece Claire Mazumdar as successor: Report
Biocon founder Kiran Mazumdar-Shaw has announced her successor. Niece Claire Mazumdar will lead the company. Claire Mazumdar is the founder and CEO of Bicara Therapeutics. She holds advanced degrees and has prior industry experience. Biocon is also undergoing structural changes. The company focuses on biosimilars and integrating artificial intelligence. Other leadership transitions are also in progress across group companies.
Biocon shares decline after USFDA issues Form 483 with five observations for Bengaluru unit
The inspection was conducted between April 20 and April 29, 2026 and covered three Biologics manufacturing units, five quality testing laboratories and two warehouses.
Biocon gains after Health Canada nod for cancer, osteoporosis drugs
Biocon shares rise after Health Canada approves Bosaya and Vevzuo denosumab biosimilars for osteoporosis and cancer bone conditions, stock up about 1.5 percent at 364.40
With sights on huge gains, Biocon to scale up AI focus
Biopharma major Biocon is significantly scaling up its adoption of artificial intelligence across its operations, from R&D to manufacturing and procurement. This strategic investment aims to achieve substantial cost savings, accelerate drug development timelines, and enhance its competitive edge in the global market.
Biocon launches biosimilars - Bosaya and Aukelso in U.S.
Biocon announced the commercial launch of Bosaya (denosumab-kyqq) and Aukelso (denosumab kyqq) in the United States.
Biocon rolls out two biosimilars in US market
Biocon has launched two new biosimilar medicines, Bosaya and Aukelso, in the United States. These drugs treat serious bone conditions. They are now available through specialty pharmacies and healthcare providers. The US Food and Drug Administration previously approved them. This launch expands Biocon's portfolio and aims to provide affordable treatment options for patients.
Biocon launches bone therapy biosimilars Bosaya, Aukelso in US market
Bosaya, a biosimilar to Prolia, and Aukelso, a biosimilar to Xgeva, are now available by prescription across the country through specialty pharmacies and healthcare providers, said the company.
Jubilant Foodworks Ltd leads losers in 'A' group
Force Motors Ltd, Bank of India, Biocon Ltd and Cholamandalam Financial Holdings Ltd are among the other losers in the BSE's 'A' group today, 07 April 2026.
Valuation Check: 9 mid-cap stocks trading well above their Industry P/E
Stocks trading above their industry price-to-earnings ratio often signal strong growth expectations or investor optimism. A StockEdge valuation scan highlights nine NSE midcap companies, including Lenskart Solutions, NTPC Green Energy and Biocon.